Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko
Korean J Intern Med. 2020;35(3):559-565. Published online 2019 May 10 DOI: https://doi.org/10.3904/kjim.2018.338
Citations to this article as recorded by 
The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
Ruochan Chen, Yinghui Xiong, Yanyang Zeng, Xiaolei Wang, Yinzong Xiao, Yixiang Zheng
Frontiers in Public Health.2023;[Epub] CrossRef
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
Sara Majd Jabbari, Khadije Maajani, Shahin Merat, Hossein Poustchi, Sadaf G. Sepanlou, Chen-Hua Liu
PLOS ONE.2021; 16(2): e0246594. CrossRef
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
Pharmacology Research & Perspectives.2021;[Epub] CrossRef
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis
Fadi Shehadeh, Markos Kalligeros, Katrina Byrd, Douglas Shemin, Eleftherios Mylonakis, Paul Martin, Erika M. C. D’Agata
Scientific Reports.2020;[Epub] CrossRef